Zenas BioPharma, Inc. Common Stock (NASDAQ:ZBIO) — Market Cap & Net Worth
Market Cap & Net Worth: Zenas BioPharma, Inc. Common Stock (ZBIO)
Zenas BioPharma, Inc. Common Stock (NASDAQ:ZBIO) has a market capitalization of $1.21 Billion ($1.21 Billion) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #8311 globally and #2285 in its home market, demonstrating a 4.71% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Zenas BioPharma, Inc. Common Stock's stock price $19.36 by its total outstanding shares 62361260 (62.36 Million). Analyse Zenas BioPharma, Inc. Common Stock (ZBIO) cash flow conversion to see how efficiently the company converts income to cash.
Zenas BioPharma, Inc. Common Stock Market Cap History: 2024 to 2026
Zenas BioPharma, Inc. Common Stock's market capitalization history from 2024 to 2026. Data shows growth from $510.74 Million to $1.21 Billion (4.04% CAGR).
Index Memberships
Zenas BioPharma, Inc. Common Stock is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.05% | #220 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #867 of 3165 |
Weight: Zenas BioPharma, Inc. Common Stock's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Zenas BioPharma, Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Zenas BioPharma, Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
226.43x
Zenas BioPharma, Inc. Common Stock's market cap is 226.43 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2024 | $510.74 Million | $5.00 Million | -$156.99 Million | 102.15x | N/A |
| 2025 | $2.26 Billion | $10.00 Million | -$377.74 Million | 226.43x | N/A |
Competitor Companies of ZBIO by Market Capitalization
Companies near Zenas BioPharma, Inc. Common Stock in the global market cap rankings as of May 4, 2026.
Key companies related to Zenas BioPharma, Inc. Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Zenas BioPharma, Inc. Common Stock Historical Marketcap From 2024 to 2026
Between 2024 and today, Zenas BioPharma, Inc. Common Stock's market cap moved from $510.74 Million to $ 1.21 Billion, with a yearly change of 4.04%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.21 Billion | -46.68% |
| 2025 | $2.26 Billion | +343.35% |
| 2024 | $510.74 Million | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of Zenas BioPharma, Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.21 Billion USD |
| MoneyControl | $1.21 Billion USD |
| MarketWatch | $1.21 Billion USD |
| marketcap.company | $1.21 Billion USD |
| Reuters | $1.21 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Zenas BioPharma, Inc. Common Stock
Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc"RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, an… Read more